AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20150769
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy plus radiotherapy
Trial: 15316509
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin sodium (5000 IU/mL)
Trial: 9602202
Drug: rhEPO 750
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEPO 750 IU/kg/week (low-dose group)
Trial: 9602202
Drug: rhEPO 1500
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEPO 1500 IU/kg/week (high-dose group)
Trial: 8030684
Drug: Thyrotropin-releasing hormone
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin-releasing hormone (400 micrograms IV four times) and betamethasone (5 mg IM four times)
Trial: 2810410
Drug: Clindamycin dosed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin dosed at 1,200 mg every 12 hours
Trial: 2810410
Drug: High-dose amikacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose amikacin (11 mg/kg)
Trial: 30016770
Drug: L-ornithine L-aspartate
RxNorm normalized name: L-ornithine L-aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ornithine L-aspartate (LOLA) 6-9 g/d for 12 weeks
Trial: 29727385
Drug: L-ornithine L-aspartate
RxNorm normalized name: L-ornithine L-aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ornithine L-aspartate (LOLA)
Trial: 26503196
Drug: Intermittent high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent high-dose interferon alfa-2b (iHDI) 20 MIU/m2 administered intravenously 5 days a week for 4 weeks then repeated every 4 months
Trial: 26503196
Drug: Standard high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard high-dose interferon alfa-2b (HDI)
Trial: 19030864
Drug: Manual lymphatic
RxNorm normalized name: PINPOINT Lymphatics Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual lymphatic drainage (MLD) therapy
Trial: 19030864
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (nonsteroidal anti-inflammatory drug, physical therapy, and therapeutic exercise program)
Trial: 16127567
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg q.d.), tetracycline (500 mg q.i.d.), and furazolidone (200 mg t.i.d.) for 7 days (LTF; n = 52)
Trial: 16127567
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg b.i.d.) and amoxicillin (1 g b.i.d.) for 1 week, plus azithromycin (500 mg q.d.) for the first 3 days (LAAz; n = 52)
Trial: 16127567
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg q.d.), tetracycline (500 mg q.i.d.), and furazolidone (200 mg t.i.d.) for 7 days (LTF)
Trial: 16127567
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg b.i.d.) and amoxicillin (1 g b.i.d.) for 1 week, plus azithromycin (500 mg q.d.) for the first 3 days (LAAz)
Trial: 10660161
Drug: Conventional biological
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional biological aortic valve replacement (Carpentier‐Edwards, n = 74)
Trial: 1971641
Drug: Ceftazidime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (2 g)
Trial: 1971641
Drug: Capsule medium
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule medium
Trial: 24149990
Drug: Conventional ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ultrasound therapy
Trial: 27386814
Drug: Game-based constraint-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Game-based constraint-induced movement therapy (CIMT)
Trial: 23413135
Drug: l-arginine aspartate
DrugBank: Arginine aspartate (DB15993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine aspartate 8 g combined with 200 mg of adenosine monophosphate (AA)
Trial: 19954529
Drug: Nitazoxanide 200
RxNorm normalized name: nitazoxanide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide 200 mg bid for 28 days (1-3 years old) or 400 mg bid for 28 days (4-11 years old)
Trial: 17382741
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tadalafil for 6 weeks
Trial: 17382741
Drug: 5/20 mg
RxNorm normalized name: Azor 5/20 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5/20 mg tadalafil for 12 weeks
Trial: 17382741
Drug: 5/20 mg
RxNorm normalized name: Azor 5/20 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5/20 mg tadalafil with placebo run-in for 12 weeks
Trial: 17382741
Drug: 5/20 mg
RxNorm normalized name: Azor 5/20 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5/20 mg tadalafil for sexually active men with erectile dysfunction
Trial: 3169109
Drug: Oral diltiazem
RxNorm normalized name: diltiazem Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diltiazem 120 mg
Trial: 28756068
Drug: Iclaprim 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iclaprim 0.8 mg/kg IV q12h
Trial: 28756068
Drug: Iclaprim 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iclaprim 1.2 mg/kg IV q8h
Trial: 28756068
Drug: Vancomycin 1
RxNorm normalized name: vancomycin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 1 g IV q12h
Trial: 26164092
Drug: Multi-component intervention
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component intervention (Group A) including pedometers, website for step registration, physical activity on prescription, motivational interviewing (10 occasions), and group consultations (12 occasions)
Trial: 20069307
Drug: 6.25 mg
RxNorm normalized name: captopril 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.25 mg bupivacaine alone
Trial: 20069307
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg bupivacaine, 25 mg mepivacaine and 0.0125 mg epinephrine
Trial: 18821691
Drug: Tocilizumab 8
RxNorm normalized name: tocilizumab 80 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab 8 mg/kg every 4 weeks for 24 weeks
Trial: 10353583
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium (1600 microg four times daily)
Trial: 7728627
Drug: Active chiropractic
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active chiropractic spinal manipulative treatment
Trial: 7728627
Drug: Sham chiropractic
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham chiropractic spinal manipulative treatment
Trial: 2045756
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg purified caffeine
Trial: 30916531
Drug: Afferent electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Afferent electrical stimulation with mirror therapy
Trial: 30916531
Drug: Sham afferent
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham afferent electrical stimulation with sham mirror therapy
Trial: 21354681
Drug: Desmopressin acetate,
RxNorm normalized name: Desmopressin Acetate, 0.2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin acetate, 0.3 μg/kg
Trial: 3895365
Drug: Bornaprine 8
RxNorm normalized name: bornaprine
DrugBank: Bornaprine (DB13619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bornaprine 8 mg/die
Trial: 27594130
Drug: Oral direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral direct factor Xa inhibitors
Trial: 20080036
Drug: Risperidone (2-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (2-6 mg/day)
Trial: 15890074
Drug: Single dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dosage of memantine
Trial: 15890074
Drug: Ascending dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending dosage of memantine over 8 days
Trial: 10073852
Drug: COER-24 verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COER-24 verapamil 240 mg titrated to 480 mg at bedtime (n = 173)
Trial: 10073852
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg titrated to 10 mg/day (n = 149)
Trial: 10073852
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg plus atenolol 50 mg/day in the A.M. (n = 154)
Trial: 2390587
Drug: Mastectomy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mastectomy treatment
Trial: 25900065
Drug: Subcutaneous rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous rituximab 1600 mg
Trial: 26947201
Drug: Intravenous rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous rituximab 500 mg/m(2)
Trial: 350491
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg triamcinolone acetonide
Trial: 22674243
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml 1% procaine HCl
Trial: 22674243
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml 0.09% saline (placebo)
Trial: 16719158
Drug: Recombinant growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant growth hormone (rGH) treatment
Trial: 16719158
Drug: No rGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No rGH treatment (Control Group)
Trial: 12534607
Drug: Betamethasone valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone valerate mousse (BVM) applied twice daily for 4 weeks
Trial: 12534607
Drug: Standard therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapies (ST) applied once or twice daily for 4 weeks
Trial: 11067784
Drug: White blood
RxNorm normalized name: Human white blood cell product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White blood cell count 0 to 5x10(9)/L
Trial: 11067784
Drug: White blood
RxNorm normalized name: Human white blood cell product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White blood cell count 5 to 10x10(9)/L
Trial: 11067784
Drug: White blood
RxNorm normalized name: Human white blood cell product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White blood cell count 10 to 15x10(9)/L
Trial: 11067784
Drug: White blood
RxNorm normalized name: Human white blood cell product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White blood cell count >15x10(9)/L
Trial: 8860884
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg daily oral progesterone
Trial: 8860884
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg daily vaginal progesterone
Trial: 1292916
Drug: Clarithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (250 mg, b.i.d.)
Trial: 1292916
Drug: Midecamycin acetate
RxNorm normalized name: Midecamycin acetate
DrugBank: Midecamycin (DB13456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midecamycin acetate (600 mg, b.i.d.)
Trial: 6430768
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ISDN (isosorbide dinitrate) acute administration
Trial: 6430768
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ISDN (isosorbide dinitrate) long-term treatment (40 mg four times daily)
Trial: 6430768
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg sublingually-administered nitroglycerin (GTN)
Trial: 19106238
Drug: 200 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g/d of a dairy drink with 5.8 mg IPP and 4.4 mg VPP
Trial: 19106238
Drug: 100 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g/d of a dairy drink with 2.7 mg IPP, 1.9 mg VPP, and 350 mg added K
Trial: 15834843
Drug: Nabilone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone (2 mg/day)
Trial: 9583393
Drug: Intravenous line
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous line placement with intradermal saline + benzyl alcohol (0.9%)
Trial: 9583393
Drug: Intravenous line
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous line placement with intradermal lidocaine (1%)
Trial: 2000823
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg beta-carotene/d
Trial: 25450123
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy dedicated to the residual limb
Trial: 21493732
Drug: Nifedipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (30 + 10 mg)
Trial: 10328392
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of autologous platelet concentrate (APC) during surgery
Trial: 27896711
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of solifenacin 6 mg plus oral controlled absorption system (OCAS™) formulation of tamsulosin (TOCAS, 0.4 mg)
Trial: 27896711
Drug: TOCAS monotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TOCAS monotherapy
Trial: 26271567
Drug: Pathogenetic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pathogenetic therapy with antihypoxant reamberin (N=64)
Trial: 26271567
Drug: Pathogenetic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pathogenetic therapy with antihypoxant reamberin and hepatoprotector remaxol (N=84)
Trial: 19188252
Drug: Rapamycin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapamycin treatment prior to exercise
Trial: 15530681
Drug: Influenza and
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza and pneumococcal vaccine
Trial: 11586492
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg/day, n = 14)
Trial: 8572850
Drug: Indapamide IR
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide IR 2.5 mg
Trial: 8572850
Drug: Indapamide SR
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide SR 2.0 mg
Trial: 8572850
Drug: Indapamide SR
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide SR 2.5 mg
Trial: 2500368
Drug: Semipermanent vascular
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semipermanent vascular access catheters (VACs) maintained without occlusive dressings, antibiotics, repeated flushings or heparin.
Trial: 966146
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered methotrimeprazine
Trial: 28017546
Drug: 1% prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% prilocaine (Xylonaest) in combination with epinephrine 1:100,000
Trial: 28017546
Drug: Ropivacaine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (10 mg Naropin, 5 ml sodium chloride, 1 ml epinephrine)
Trial: 23295794
Drug: Tremelimumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab (15 mg/kg once every 90 days)
Trial: 23295794
Drug: Standard-of-care chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care chemotherapy (temozolomide or dacarbazine)
Trial: 19762088
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone (0.2mg/kg every 6h) with nebulized L-epinephrine (0.5mg/kg every 4h)
Trial: 19762088
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone (0.2mg/kg every 6h) without nebulized L-epinephrine
Trial: 19762088
Drug: Control groups
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control groups received nebulized or intravenous isotonic saline solution, or both
Trial: 16913269
Drug: H1-antihistamine (loratadine)
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1-antihistamine (loratadine) + intranasal glucocorticosteroid (mometasone furoate)
Trial: 16913269
Drug: Intranasal glucocorticosteroid
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal glucocorticosteroid (mometasone furoate) alone
Trial: 15605620
Drug: Hypericum extract
RxNorm normalized name: Hypericum extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum extract STW 3-VI 900 mg once daily
Trial: 9021907
Drug: MgSO4 infusion
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MgSO4 infusion
Trial: 11771826
Drug: MgSO4 and
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MgSO4 and GIK infusion after 10 hours
Trial: 9027913
Drug: Antimalarial chemoprophylaxis
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antimalarial chemoprophylaxis in primigravidae
Trial: 8098059
Drug: Taxotere 6-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxotere 6-hour infusion at a maximally tolerated dose of 100 mg/m2
Trial: 8098059
Drug: Taxotere 2-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxotere 2-hour infusion at a maximally tolerated dose of 115 mg/m2
Trial: 30544179
Drug: Spirited Life
RxNorm normalized name: TURPENTINE SPIRITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirited Life wellness intervention including a 10-week online weight-loss program and monthly health coaching for 24 months
Trial: 21706145
Drug: romiplostim (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: romiplostim (3 μg/kg weekly for 12 weeks)
Trial: 1591091
Drug: Tamoxifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment for 5 years
Trial: 11823690
Drug: 5-fluorouracil (5-FU),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil (5-FU), 600 mg/m2 (arm I)
Trial: 11823690
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) 500 mg/m2 intravenous bolus and interferon-alpha, 5 MU subcutaneously, three times a week (arm II)
Trial: 11823690
Drug: Leucovorin 200
RxNorm normalized name: leucovorin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin 200 mg/m2 in 2-hour infusion and 5-FU 500 mg/m2 intravenous bolus (arm III)
Trial: 171161
Drug: Intragastric fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intragastric fat administration (soya bean triglyceride-egg yolk phospholipid emulsion, Intralipid)
Trial: 171161
Drug: Intravenous fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fat administration (soya bean triglyceride-egg yolk phospholipid emulsion, Intralipid)
Trial: 25197737
Drug: Game-based oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Game-based oral health education (snakes and ladders game combined with flash cards)
Trial: 25197737
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral health education (flash cards once daily for 7 days)
Trial: 25603438
Drug: Nepafenac ophthalmic
RxNorm normalized name: nepafenac ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nepafenac ophthalmic suspension 0.1%
Trial: 9615303
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy for 12 months
Trial: 2481787
Drug: Bisoprolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (10 mg/day)
Trial: 1982059
Drug: Celiprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (200 mg/day)
Trial: 2684023
Drug: Terbinafine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 500 mg daily for 6 weeks